Background: Subcutaneous malignant tumors are often treated by non-specialized clinicians in musculoskeletal oncology. While the resection of subcutaneous tumors appears technically feasible, unplanned resection of malignant tumors can result in a devastating clinical outcome. The aim of this study was to evaluate the potential estrangement in the awareness of and the treatment strategy for the patients with subcutaneous soft tissue tumors between musculoskeletal oncologists and non-specialized clinicians. Methods: A questionnaire probing the clinical assessment of subcutaneous tumors was sent to orthopedic surgeons, dermatologists, plastic surgeons, and general surgeons. Results of the questionnaire were statistically analyzed. Results: One hundred sixteen clinicians out of 150 responded to the questionnaire; the response rate was 77.3%. Among those, 46 clinicians had treated subcutaneous tumors. Thirty-nine of these 46 clinicians (27 musculoskeletal oncologists and 12 non-specialized clinicians) preoperatively performed enhanced MRI for diagnostic evaluation. Preoperative incisional biopsy to confirm the pathological diagnosis was performed by 36 of the 46 clinicians (29 musculoskeletal oncologists and seven non-specialized clinicians). These results indicate that musculoskeletal oncologists perform preoperative enhanced MRI (P = 0.08) and biopsy (P < 0.01) more frequently than nonspecialized clinicians. The recognition rate of 'myxofibrosarcoma' was 60.8% among clinicians with an experience with sarcoma treatment (25 musculoskeletal oncologists and three nonspecialized clinicians). The recognition rate of 'myxofibrosarcoma' between musculoskeletal oncologists and non-specialized clinicians was statistically significant (P < 0.01). Conclusions: Preoperative evaluations for subcutaneous tumors are more often inappropriate in non-specialized clinicians than those who are. Therefore, it will be mandatory to raise the awareness of this condition to improve the clinical outcome of patients with subcutaneous tumors.
Introduction
Soft tissue tumors, whether benign or malignant, often arise in the subcutaneous tissue (1) . The relatively smaller sizes of these tumors may lead clinicians with relatively little experience in treating sarcomas to perform surgical resections without thorough preoperative examinations such as enhanced magnetic resonance imaging (MRI) or incisional biopsy. In fact, the treatment guidelines for subcutaneous soft tissue tumors (SSTTs) indicate that it is acceptable to perform total resection (excisional biopsy) for tumors smaller than 5 cm in diameter (2) . This is because such tumors are mostly benign or are still in their early disease phases even if any malignant histological indicators are present. However, once diagnoses of sarcoma are made following such unplanned resections, tumor-specialized clinicians to whom the patients are referred face difficulties in managing these patients owing to their having undergone misguided surgeries without proper preoperative diagnostic procedures (3) (4) (5) (6) .
When planning surgical interventions for SSTTs, clinicians should always consider the possibility of sarcoma, regardless of the lesion's size. Myxofibrosarcoma is a prime example of a malignant SSTT (7) . Inadequate or improper resection necessitates additional procedures to obtain wider margins because of sarcomas' high invasiveness and local recurrence rates. A second surgery may sometimes become a radical procedure that could have been avoided if the initial surgery had been performed properly (8) . Nevertheless, sarcomas of superficial origin are not frequently observed; therefore, it is likely that non-specialized clinicians may be treating small subcutaneous masses without realizing that such tumors may actually be malignant (4) (5) (6) .
In order to achieve satisfactory outcomes for subcutaneous sarcoma patients, it is crucial to reduce the risk of inadequate resection at initial surgery by all clinicians, regardless of their subspecialties. In this study, we conducted a questionnaire-based survey of individual medical practitioners to inquire about the diagnostic and surgical strategies employed for treating SSTTs. The study, which also aimed to clarify the factors responsible for mistakes that arise in initial treatment plans, explored the differences in tumor treatment approaches between clinicians who are specialized in musculoskeletal oncology and those who are not. To the best of our knowledge, this is the first and unique questionnaire study on SSTTs, in which the questionnaires were answered by surgeons from different specialties and backgrounds.
Materials and methods
Questionnaires were sent to 150 clinicians; questions inquired about [1] the specialties of the respondents, [2] plans used to treat patients with SSTTs smaller than 5 cm in diameter, [3] knowledge about myxofibrosarcoma, one of the most frequent subcutaneous soft tissue sarcomas, and [4] any experience with marginal resections of superficial sarcomas that had not been diagnosed or suspected as such preoperatively (Table 1 ). Regarding point [2] , more detailed questions included [2a] whether they intended to diagnose and treat such patients personally or refer them to musculoskeletal oncologists, [2b] whether MRI with gadolinium enhancement was performed, and [2c] whether biopsy was performed during the course of treatment. Respondents were randomly chosen from among orthopedic surgeons, plastic surgeons, dermatologists, and general surgeons at Keio University Hospital and related hospitals. Responses were grouped into two, those from musculoskeleatal oncologists and those from non-specialized clinicians in musculoskeletal oncology, and were statistically compared by using the chi-square test (9) . The JMP statistical software package version 12.0.1 (SAS Institute, Japan) was used for statistical analysis. Results with P values <0.01 were regarded as statistically significant. This study was approved by ethical review board of Keio University Hospital.
Results
Of 150 surveys sent, 116 completed forms were returned; the valid response rate was 77.3%. Respondents comprised 32 musculoskeletal oncologists (27.6%) and 84 non-specialized clinicians in musculoskeletal oncology (72.4%: 29 general orthopedic surgeons, 25 dermatologists, and 30 plastic surgeons) (Fig. 1) . Forty-six respondents (39.6%) were involved in both diagnosis and treatment of SSTT patients. On the other hand, 70 (60.4%) chose to refer such patients to musculoskeletal oncologists directly after first contact ( Fig. 2A) . Twenty-nine of the 46 clinicians (63%) who claimed to take responsibility for the treatment of SSTT patients were musculoskeletal oncologists (Fig. 2B ). Of the same 46 physicians, 39 (84.7%) performed enhanced MRI as a mandatory preoperative examination, while seven (15.3%) did not. The majority of respondents who performed enhanced MRI tended to be musculoskeletal oncologists (27/39), although the proportion was not significant (P = 0.08, Fig. 3A ). Biopsy to confirm pathological diagnosis prior to planning total resection was performed by 36 clinicians (78.2%), including 29 musculoskeletal oncologists. As for nonspecialized clinicians in musculoskeletal oncology, only seven claimed that it was necessary to perform a preoperative biopsy, and 10 stated that they had never performed such a procedure. This revealed a significantly lower rate of biopsy among non-specialized clinicians in musculoskeletal oncology than among musculoskeletal oncologists (P < 0.01, Fig. 3B ). The next question inquired about familiarity with soft tissue sarcomas of superficial origin, namely myxofibrosarcoma. Twenty-eight of 46 physicians who were directly involved in treating SSTTs (60.8%) recognized this disease, only three of whom were non-specialized clinicians in musculoskeletal oncology. There was a significant difference in awareness of such tumors between musculoskeletal oncologists and non-specialized clinicians in musculoskeletal oncology (P < 0.01; Fig. 4) . Notably, 21 of the 46 clinicians who had treated SSTTs personally (45.6%) experienced an unexpected diagnosis of malignancy. Myxofibrosarcoma was the most frequent with eight cases, the remainder included five synovial sarcomas, five undifferentiated pleomorphic sarcomas (UPS), three epithelioid sarcomas, three dermatofibrosarcoma protuberans (DFSPs), four liposarcomas and two clear-cell sarcomas (Fig. 5) .
Discussion
In 2010, there were 10 520 soft tissue sarcomas newly diagnosed in the United States, as well as 3920 deaths from this disease (10).
Those arising in subcutaneous tissues accounted for up to 20% of all soft tissue sarcomas (11) . Because such malignancies are relatively rare, they may be treated by surgeons who may not necessarily have experience in sarcomas (1). In our study, almost half of the 46 clinicians who were involved in the treatment of soft tissue tumors were not specialized in musculoskeletal oncology. Among non-specialist clinicians who decided against personally handling treatment, only 80% succeeded in directly consulting trained musculoskeletal oncologists. Inexperienced clinicians run the risk of underestimating the malignant potential of a yet-undiagnosed tumor; therefore, they forgo important preoperative diagnostic procedures such as MRI and incisional biopsy (1) . The initial treatment of SSTTs is one of the key factors that determines disease outcome; thus, the entire course of treatment ought to be supervised by musculoskeletal oncologists (8, 11, 12) .
In our study, non-specialized clinicians in musculoskeletal oncology performed biopsies less frequently; they also tended to perform fewer enhanced MRIs. Biopsies are essential for devising a rational treatment plan unless the tumor is smaller than 3 cm in diameter, where diagnosis by resection biopsy is permissible because of the low possibility of sarcoma (13) . Meanwhile, when treating tumors larger than the approximate size of a golf ball (14) , incisional or needle biopsies are strongly recommended (13) because such tumors are more likely to be malignant according to a study of 1460 bone and soft tissue sarcoma cases (14) . MRI also plays a crucial role in determining a tumor's actual size, determining the presence of daughter lesions, and pinpointing the tumor's anatomical location in relation to the neighboring neurovascular bundles; each of these parameters is crucial when devising a treatment strategy (15, 16) . Furthermore, accurate information regarding the tumor location or disease stage of superficial sarcomas such as DFSP or myxofibrosarcoma is difficult to obtain without enhanced MRI or other qualitative imaging studies (15, 17) . MRI can even determine the histological diagnosis in one-third or one-fourth of soft tissue tumors, where enhanced signal patterns, signal heterogeneity or tumor necrosis on typical T1-and T2-weighted MRIs are signs of a probable malignancy.
As shown in this study, basic awareness of soft tissue tumor treatment is not common among non-specialized clinicians in musculoskeletal oncology (5, 6) . This may be because sarcoma is so rare that it accounts for less than 1% of all malignant tumors (4,5); nonspecialized clinicians in musculoskeletal oncology encounter such cases less often than once every three years (5, 6) . In fact, our study revealed that familiarity with superficial sarcomas, among which we selected myxofibrosarcoma as a representative disease, is significantly lower among non-specialized clinicians in musculoskeletal oncology than among musculoskeletal oncologists; making non-specialized clinicians in musculoskeletal oncology far less likely to suspect that a presentation of a superficial tumor could be malignant. Therefore, they see no reason to order a biopsy or MRI.
Inappropriate resection without contingencies for the possibility of worse diagnosis leads to poor patient outcomes (8, 13) . Our study showed that almost half of the surgeons with any experience in SSTT treatment had encountered an incorrectly diagnosed sarcoma patient who had received insufficient treatment. Among such cases, the most frequent diagnoses were myxofibrosarcoma and UPS followed by DFSP and liposarcoma; all are known to arise in the subcutaneous tissue (11, 18) . UPS, leiomyosarcoma, DFSP, angiosarcoma, myxofibrosarcoma and liposarcoma should always be included in the differential diagnosis when treating SSTTs.
The physicians we surveyed also encountered epithelioid sarcoma, synovial sarcoma and clear-cell sarcoma; these do not always exhibit malignant characteristics, and can easily be misdiagnosed as benign tumors. Epithelioid sarcoma is often overlooked in clinical practice because it is asymptomatic in its early phase and grows slowly as a subcutaneous mass or an ulcer (19) . Synovial sarcoma is also a slow-growing tumor and is known to present 'pseudo-benign imaging' (16); its characteristic 'triple sign' is sometimes missed in superficial cases (20) . Clear-cell sarcoma is a rare soft tissue sarcoma and is sometimes described as 'malignant melanoma of the soft parts' because of its unique histological presentation of melanincontaining tumor cells (7) . This tumor type usually grows in contact with the tendons and fascia, and is most commonly observed in the Achilles tendon and plantar fascia (21) . Intracellular melanin deposits, found in two-thirds of all cases, cause T1-weighted signal elongation on MRI that is not reduced by fat-suppression; this key finding sometimes leads to the correct preoperative diagnosis (22, 23) . On the other hand, T2-weighed imaging and patterns observed with gadolinium enhancement are not useful. Tissue edema surrounding the tumor and the lack of central necrosis may cause a medical practitioner to incorrectly diagnose clear-cell sarcoma as a benign condition such as bursitis.
Our study revealed that non-specialized clinicians in musculoskeletal oncology were not familiar with the basic approach to SSTTs. Trained musculoskeletal oncologists were more responsible than others for establishing treatment strategies based on proper preoperative investigations, including the use of enhanced MRI and biopsy. Clinicians of other specialties tended to underestimate the malignant potential of the SSTTs. Some performed inadequate intralesional resections, which risked leading to poor outcomes. They did not appear attuned to the fact that subcutaneous sarcoma; i.e. myxofibrosarcoma and other SSTTs, may sometimes be encountered in daily clinical practice. Educational information, especially on the diagnosis and treatment of sarcomas of superficial origin, should be recognized as being of great importance for achieving better outcomes in subcutaneous sarcoma (or soft tissue tumor) treatment. Effective and efficient methods to educate non-specialized clinicians in musculoskeletal oncology surgeons is critical for enabling them to better understand and treat tumors that may be malignant. It is expected that the results of this study will be the basic data necessary for nonspecialized clinicians' education.
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